Data sourcesSEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company
REGNREGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Disclosed transactions60
Buys / sells0 / 40
Max Insider Score48
Connections16with evidence
REGN · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 44 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $2.43M 2,522 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
|
48
REGNREGENERON PHARMACEUTICALS, INC. Open-market sale |
| Nov 4, 2026 traded Nov 2, 2026 |
| 34 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $194K 200 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 26 | FRFenimore Christopher R.EVP Finance CFO | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | $2.29M 6,000 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 26 | FRFenimore Christopher R.EVP Finance CFO | REGNREGENERON PHARMACEUTICALS, INC. Tax withholding | F | $4.03M 4,243 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 12 | FRFenimore Christopher R.EVP Finance CFO | REGNREGENERON PHARMACEUTICALS, INC. Gift | G | — 15 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 9 | FRFenimore Christopher R.EVP Finance CFO | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 6,000 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 37 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $519K 540 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 44 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $4.18M 4,338 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 44 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $2.58M 2,670 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 44 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $1.47M 1,522 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 40 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $1.01M 1,040 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 9 | | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 7,830 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 9 | | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 7,439 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 26 | LJLarosa Joseph JEVP General Counsel and Secret | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | $4.69M 12.3K sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 26 | LJLarosa Joseph JEVP General Counsel and Secret | REGNREGENERON PHARMACEUTICALS, INC. Tax withholding | F | $8.26M 8,686 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 44 | LJLarosa Joseph JEVP General Counsel and Secret | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $3.80M 3,939 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 37 | LJLarosa Joseph JEVP General Counsel and Secret | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $509K 527 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 9 | LJLarosa Joseph JEVP General Counsel and Secret | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 12.3K sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 26 | | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | $2.95M 7,830 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 22 | | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | $2.83M 7,439 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 40 | | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale | SELL | $1.18M 1,224 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC FORM 4 | |
| 13 | GKGuarini KathrynDirector | REGNREGENERON PHARMACEUTICALS, INC. Option exercise · 10b5-1 plan | M | $288K 400 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC FORM 4 | |
| 25 | GKGuarini KathrynDirector | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $360K 400 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC FORM 4 | |
| 7 | GKGuarini KathrynDirector | REGNREGENERON PHARMACEUTICALS, INC. Option exercise · 10b5-1 plan | M | — 400 sh | Oct 30, 2026 | Nov 3, 2026 traded Oct 30, 2026 | +4d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $11K 14 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $56K 74 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $42K 55 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $9,242 12 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $94K 121 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 11 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $292K 376 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $30K 38 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 11 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $354K 454 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $167K 219 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 16 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Option exercise · 10b5-1 plan | M | $6.49M 17.0K sh | Oct 13, 2026 | Oct 15, 2026 traded Oct 13, 2026 | +2d | SEC FORM 4 | |
| 16 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Tax withholding · 10b5-1 plan | F | $9.70M 12.9K sh | Oct 13, 2026 | Oct 15, 2026 traded Oct 13, 2026 | +2d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $18K 24 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $21K 27 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $147K 192 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $98K 127 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $218K 283 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $163K 211 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $173K 224 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $51K 66 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 11 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $296K 380 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 11 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $361K 463 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $39K 50 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 0 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Option exercise · 10b5-1 plan | M | — 17.0K sh | Oct 13, 2026 | Oct 15, 2026 traded Oct 13, 2026 | +2d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $19K 25 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $4,523 6 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $26K 35 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 5 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $12K 16 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $207K 271 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $214K 279 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 8 | MJMurphy Andrew JCo-Chief Scientific Officer | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $81K 105 sh | Oct 14, 2026 | Oct 15, 2026 traded Oct 14, 2026 | +1d | SEC FORM 4 | |
| 15 | GKGuarini KathrynDirector | REGNREGENERON PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $340K 400 sh | Sep 2, 2026 | Sep 3, 2026 traded Sep 2, 2026 | +1d | SEC FORM 4 | |
| 7 | GKGuarini KathrynDirector | REGNREGENERON PHARMACEUTICALS, INC. Option exercise · 10b5-1 plan | M | — 400 sh | Sep 2, 2026 | Sep 3, 2026 traded Sep 2, 2026 | +1d | SEC FORM 4 | |
| 13 | GKGuarini KathrynDirector | REGNREGENERON PHARMACEUTICALS, INC. Option exercise · 10b5-1 plan | M | $288K 400 sh | Sep 2, 2026 | Sep 3, 2026 traded Sep 2, 2026 | +1d | SEC FORM 4 | |
| 26 | FRFenimore Christopher R.EVP Finance CFO | REGNREGENERON PHARMACEUTICALS, INC. Tax withholding | F | $3.74M 4,599 sh | Aug 18, 2026 | Aug 20, 2026 traded Aug 18, 2026 | +2d | SEC FORM 4 | |
| 9 | FRFenimore Christopher R.EVP Finance CFO | REGNREGENERON PHARMACEUTICALS, INC. Option exercise | M | — 6,283 sh | Aug 18, 2026 | Aug 20, 2026 traded Aug 18, 2026 | +2d | SEC FORM 4 | |
REGENERON PHARMACEUTICALS, INC. PAC